The Changes of Four Cell-Resource Biomarkers in Rats with Acute Respiratory Distress Syndrome
Jinle Lin,Min Shi,Yanxiu Lu,Jian Wei,Xuan Fu,Shiyong Zeng,Jianbin Ye,Wuyuan Tao,Qingli Dou,Wenwu Zhang
DOI: https://doi.org/10.3760/cma.j.issn.1671-0282.2020.11.002
2020-01-01
Abstract:Objective:To provide experimental evidence for panel determination in clinical practice, we characterized the early changes of surfactant proteins B (SP-B), plasminogen activator inhibitor-1 (PAI-1), high-mobility group box B1 (HMGB1) and soluble receptor for advanced glycation end products (sRAGE) in acute respiratory distress syndrome (ARDS) induced by lipopolysaccharide (LPS).Methods:In the Institute of Cardiopulmonary Cerebral Resuscitation, Sun Yat Sen University, 36 SD rats were randomly (random number) divided into the LPS group and control group. ARDS rat model in the LPS group was established by intrapulmonary injection of LPS (10 μg/mL) synchronously intrapulmonary injection of saline in the control group. Serum, bronchoalveolar lavage fluid (BALF) and lung tissues were collected at 6, 12 and 24 h after ( n=6 at each time point). After confirmed the success of ARDS model by arterial blood gas (PaO 2) and pathology, we determinated the expressions of SP-B, PAI-1, HMGB1 and sRAGE by enzyme linked immunoassay, immunohistochemistry and Western blot. Paired t test and repeated measurement ANOVA were used for comparison of these biomarkers between the two groups. Results:Progressively decreases of PaO 2 (80.38±1.74 vs 84.17±1.96; 72.20±1.70 vs 81.26±1.57; 68.52±2.45 vs 81.45±1.51) and synchronously worse deterioration at HE pathology were found in the LPS group than those in the control group ( P<0.05). Compared to the control group, a progressively significant increases in HMGB1 (ng/mL) (0.34±0.08, 0.43±0.12, 0.50±0.03), PAI-1 (ng/mL) (40.38±3.06, 50.02±4.82, 57.34±4.67) and SP-B (ng/mL) (2.21±0.11, 2.74±0.15, 3.07±0.28) but significant decreases at sRAGE (ng/mL) (0.17±0.04, 0.14±0.04, 0.11±0.02) were revealed in the serum of LPS group ( P<0.05). Another similarly significant increases in HMGB1 (ng/mL) (0.08±0.02, 0.13±0.02, 0.21±0.03), PAI-1 (ng/mL) (48.88±4.17, 56.66±4.01, 65.83±4.96) and SP-B (ng/mL) (0.68±0.13, 0.80±0.17, 1.12±0.14), but significant decreases at sRAGE (ng/mL) (0.14±0.05, 0.12±0.02, 0.11±0.02) in the BALF of the LPS group compared with those in control group ( P<0.05). Immunohistochemistry showed a consistent up-regulating started at 6 h appeared at PAI-1 (from lung interstitium to lung parenchyma), HMGB1 and SP-B (from lung parenchyma to lung interstitium) while a down-regulating at sRAGE in the LPS group. Western blot showed the elevated expression of SP-B, PAI-1 and HMGB1 but the descent expression of sRAGE following the treating time in the LPS group. Conclusions:In the early stage of ARDS, SP-B, PAI-1 and HMGB1 synchronously changes in serum, and BLAF and lung tissue had the similar tendency, of which can help clinician to early diagnose and identify ARDS by choosing one or combining the biomarkers.